In addition, we identified for the first time beneficial down-regulation of the SERPINA1, APOC3, CD99, CPSF6, CRNN, SERPINA6, HBA2, MB, VGF, PIGR, and TTR urinary peptides by GLP-1R agonist treatment in T2DM patients, which are collectively reported in the literature at elevated levels in T2DM and its associated diseases, playing an important role in increased inflammation, increased insulin secretion, imbalance in glucose homeostasis, and reduced eGFR, amongst others. This evidence concerns the gene INS and type 2 diabetes mellitus.